Slide-image and result integrity
Diagnostic decisions ride on whole-slide images and analyzer results - the integrity and source attribution of those artifacts from scanner/analyzer through middleware to LIS must be enumerated and tested.
Cybersecurity for whole-slide imaging, AI pathology, and connected lab-automation platforms.
Digital pathology and lab automation sit at the intersection of large-image workflows, AI-assisted diagnosis, and deep LIS/LIMS integration. Whole-slide imaging scanners produce multi-gigabyte images that flow into image-management systems and increasingly into FDA-cleared AI modules; lab-automation lines connect pre-analytic, analytic, and post-analytic instruments through middleware that's historically been a recurring CVE source. We build cybersecurity packages tuned to slide-image integrity, AI model governance, and the LIS/LIMS trust boundary.
Diagnostic decisions ride on whole-slide images and analyzer results - the integrity and source attribution of those artifacts from scanner/analyzer through middleware to LIS must be enumerated and tested.
FDA-cleared AI modules introduce model files, weight delivery, inference servers, and PCCP-governed updates - the SBOM and threat model must treat them as their own subsystem.
Vendor middleware between analyzers and LIS/LIMS is a documented recurring source of CVEs and account-credential abuse - continuous monitoring and a postmarket plan that addresses middleware specifically are required.
Pathology cloud platforms that support remote review and second-opinion sharing add multi-tenant authorization and cross-institution data-residency concerns to the threat model.
Digital pathology and lab automation combine gigabyte-scale slide images, AI-assisted diagnosis, and deep LIS/LIMS integration. Vendor middleware is the recurring CVE source; cloud second-opinion platforms add cross-institution multi-tenancy.
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Digital pathology and lab-automation incidents combine documented vendor-middleware vulnerabilities (notably BD Synapsys), DICOM and image-management toolkit CVEs, and the broader pattern of HL7/ASTM lab protocols operating without native authentication on hospital networks.
Historical incidents
CISA advisory ICSMA-22-256-01 disclosed multiple vulnerabilities in BD Synapsys, the laboratory informatics platform, including authentication and authorization weaknesses affecting microbiology lab data and workflow integrity.
CISA ICSMA-22-256-01
Published CVEs in widely deployed DICOM parsing and image-management libraries (DCMTK, Orthanc, dcm4che, OpenSlide families) repeatedly affect downstream consumers including digital-pathology scanners and image-management systems. Reviewers expect explicit testing of ingest paths and parser robustness, especially as DICOM-WSI deployment broadens.
Vendor middleware connecting analyzers and pathology scanners to LIS/LIMS has a documented history of credential-custody and service-tunnel incidents across the broader IVD and lab-automation space. The pattern informs how reviewers evaluate digital-pathology postmarket plans.
Active threat scenarios
Synapsys-class root cause: lab-informatics middleware with weak auth allows unauthorized reads or modifications to lab data and workflow state - directly affecting result integrity.
Substitution or tampering of slide images or analyzer results anywhere between scanner/instrument and LIS produces a clinical-decision hazard; integrity must be end-to-end, not point-to-point.
Unsigned or weakly signed model and weight delivery to a cleared AI pathology module allows substitution that changes classification behavior - AAMI CR515:2025 considerations apply.
Cross-institution review platforms expose BOLA, tenant-separation, and residency concerns at scale; clinician account takeover compounds the impact.
What FDA reviewers cite
Digital pathology and lab automation combine large-image workflows, AI-assisted diagnosis, and deep LIS/LIMS integration with vendor middleware that has historically been a recurring CVE source.
Cleared AI modules carry their own SBOM, model files, inference stack, and PCCP-governed update path; the threat model and submission must treat them distinctly from the host application.
Middleware service accounts and vendor remote-service tooling are the recurring incident pattern in this segment; the postmarket plan must address them as a continuous surface.
HL7/ASTM and many DICOM deployments lack native authentication; the architecture must document and test the compensating network and middleware controls that hold the boundary.
Pathology cloud review platforms cross institutional and jurisdictional boundaries; tenant separation, residency, and BOLA on case data are first-class concerns.
Standards & deliverables
Six deliverables FDA and notified bodies expect across MedTech, with the digital pathology / lab automation-specific wrinkle on each row. Use it as a scoping checklist before you brief vendors or your QA team.
Machine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component.
Continuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path.
Black/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling.
STRIDE-per-interface threat model with documented mitigations and residual-risk acceptance.
Signed firmware/software updates with rollback protection, integrity verification, and staged rollout.
Public CVD policy, intake channel, and SLAs for triage, fix, and customer communication.
IVD diagnostics covers analyzer-led workflows where the analyzer produces a structured result. Digital pathology adds gigabyte-scale image data, AI-assisted diagnosis on top of those images, and a pathologist-in-the-loop review workflow that often spans multiple institutions via cloud second-opinion platforms. The threat model has to address image integrity and AI module governance on top of the LIS integration concerns shared with IVD.
AI modules are scoped as their own subsystem: model file integrity, signed weight delivery, inference-server hardening, update path under a PCCP, adversarial-input resistance, and drift/performance monitoring. The SBOM includes the model and the inference stack, and AAMI CR515:2025 is referenced for ML-enabled device considerations where applicable. Findings tie back to the device-level threat model so the integrated system view stays coherent.
Yes. The chain - analyzer or scanner, middleware, LIS/LIMS, EHR result-delivery - is exercised as a single trust boundary. HL7/ASTM and DICOM-WSI traffic are tested for authentication and integrity where the protocol supports it and for compensating controls where it doesn't. Middleware service accounts, vendor remote-service tooling, and the credential-custody story are first-class scope items because they're the recurring source of incidents in this segment.
Cloud review platforms are scoped as their own system: multi-tenant authorization, BOLA on case data, clinician account takeover, cross-institution data-residency, and the export/sharing surface. Findings on the cloud are tied back to the scanner threat model so the system view stays coherent for the FDA reviewer and for hospital procurement.
Lab automation tracks and pre-/post-analytic instruments share the LIS/middleware concerns and the long-deployed-fleet concerns of digital pathology. We scope them together when manufacturers ship both, with automation-specific concerns (track control, robotic-arm safety, sample-handling integrity) called out separately.
For a whole-slide imaging scanner with image-management system and AI module, end-to-end premarket cyber work runs 10-14 weeks. Threat modeling and SBOM front-load in weeks 1-4, pen testing across scanner, image-management, AI module, and LIS integration runs in weeks 4-11, and the consolidated submission package closes in the final weeks - all under a written deficiency commitment.
Slide-image integrity, AI model governance (AAMI CR515:2025), LIS/middleware testing, and cloud second-opinion assessment.
"Blue Goat Cyber's depth of expertise was impressive. We had no in-house cybersecurity experience, and their team guided us through every step of the FDA process. The penetration testing and SBOM testing were thorough and gave us complete confidence."
Cybersecurity for whole-slide imaging, AI pathology, and connected lab-automation platforms.
